Circular Bivalent Aptamer Chimeras Leveraging LDLR-Mediated Lysosomal Shuttling for Targeted Protein Degradation.
A lysosome-targeting degradation platform based on circular bivalent aptamer chimeras (CBACs), which simultaneously engage the lysosomal shuttle receptor LDLR and target membrane proteins, which demonstrates efficient and selective degradation of two cancer-therapeutically relevant membrane proteins in multiple cancer cells, leading to apoptosis and reduced invasion and migration.